This article was originally published in The Gray Sheet
Large-scale manufacturing of the non-invasive glucose monitoring system's consumable AutoSensor component by supplier Corium gains FDA approval via PMA supplement, Cygnus announces Aug. 7. The company plans to perform final assembly of the wristwatch-like monitor at its own manufacturing facility to reduce costs, and plans to file a related PMA supplement. The device was approved in March and a full-scale launch is expected by year-end (1"The Gray Sheet" March 26, 2001, p. 13)
You may also be interested in...
Cygnus plans to kick off a pilot marketing program in April targeting 100-150 Type 1 diabetes patients to gauge firsthand consumer experience with the GlucoWatch Biographer. The non-invasive glucose monitoring system was approved by FDA on March 22.
The UK has approved the mRNA-based vaccine just nine days after receiving the final Phase III results from Pfizer.
As the MHRA prepares to grant approval to the Oxford/AstraZeneca vaccine, Wockhardt is set to supply 100 million doses for the UK government’s own use and its WHO commitments. The company is also in talks with global vaccine developers to manufacture their COVID-19 vaccines for emerging economies